Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2025-04-22 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
关于对会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (中汇会计师事务所) for the 2024 audit engagement. It discusses the auditor's qualifications, independence, audit procedures, and the company's assessment of the auditor's work for the 2024 fiscal year. It is not the audit report itself but an assessment of the auditor's performance and compliance with auditing standards. The document length is short (1462 characters) and it does not contain financial statements or detailed audit results. This fits the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-22 Chinese
2024年度独立董事述职报告（石美金）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2024" from Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, audit committee participation, review of financial and internal control matters, and oversight of fundraising and equity distribution. The content focuses on the independent director's duties and opinions regarding governance and compliance during the fiscal year 2024. It is a detailed report on board/management activities and oversight rather than a financial report, earnings release, or regulatory announcement. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 4099 characters, which is sufficient for a substantive report rather than a brief announcement or certification. Hence, the classification is MANG with high confidence.
2025-04-22 Chinese
审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report by the Audit Committee on the performance of the accounting firm for the year 2024. It discusses the audit firm's qualifications, the supervisory role of the Audit Committee, and the audit process for the company's 2024 financial report. It does not contain the actual audit report or financial statements but rather an assessment and oversight report on the auditor's performance. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and evaluations related to audit activities, excluding full annual reports. The document length is 1559 characters, which is sufficient for a detailed evaluation report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2024
2025-04-22 Chinese
2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2025 first extraordinary general meeting of shareholders of Jiangxi New Ganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and votes. The content focuses on the declaration of voting results for specific proposals regarding the use of idle funds and fundraising cash management. There are no financial statements or detailed financial data presented, nor is this a report or presentation. The document is clearly a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and it is not merely announcing the availability of a report but providing the actual voting results and resolutions passed at the meeting.
2025-04-21 Chinese
北京德恒（杭州）律师事务所关于江西新赣江药业股份有限公司2025年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedural compliance of a company's 2025 first extraordinary general meeting (临时股东大会). It details the convening procedures, attendance, voting procedures, and results of the shareholders' meeting. It does not contain financial statements or financial performance data, nor is it a report or announcement of financial results. The document is focused on legal compliance and validation of the shareholders' meeting process and outcomes. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it includes official voting results and legal opinions on the meeting's validity.
2025-04-21 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司使用闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of idle raised funds by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. for cash management. It references regulatory approvals, fundraising details, investment decisions, risk controls, and the need for shareholder meeting approval. The document is not a financial report itself but a regulatory compliance and verification statement related to the use of raised funds. It does not contain financial statements or earnings data, nor is it a brief announcement or a report publication notice. It fits best as a Regulatory Filing (RNS) because it is a compliance-related disclosure that does not fit other specific categories like capital update or audit report.
2025-04-02 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.